Sertindole: efficacy and safety in schizophrenia

Area of Science:

• Pharmacology
• Neuroscience
• Psychiatry

Background:

• Sertindole is an atypical antipsychotic targeting dopamine D2, serotonin 5-HT2A/5-HT2C, and alpha1-adrenoreceptors.
• Preclinical data indicate preferential action on limbic and cortical dopaminergic neurons.
• Clinical trials confirm efficacy at low dopamine D2 occupancy levels.

Purpose of the Study:

• To evaluate the efficacy and safety profile of sertindole as an antipsychotic medication.
• To compare sertindole's effects with other antipsychotics, particularly risperidone.
• To identify patient populations that may benefit from sertindole treatment.

Main Methods:

• Review of preclinical studies and clinical trial data.
• Analysis of pharmacodynamic properties, including receptor affinity and D2 occupancy.
• Examination of adverse event profiles and comparison with placebo and other antipsychotics.
• Assessment of efficacy in positive and negative symptoms of schizophrenia.

Main Results:

• Sertindole demonstrates efficacy at low dopamine D2 occupancy, with a long half-life and stable plasma levels.
• Low incidence of extrapyramidal side effects and tardive dyskinesia observed.
• Sertindole lacks sedative effects, unlike many other antipsychotics.
• QTc prolongation is a noted side effect, but large analyses do not link sertindole to increased all-cause mortality.
• Equivalent efficacy to risperidone for positive symptoms; mixed results for negative symptoms.
• Adverse events like weight gain, rhinitis, and decreased ejaculation volume were more common than placebo.

Conclusions:

• Sertindole is an effective antipsychotic with a favorable side-effect profile regarding extrapyramidal symptoms and sedation.
• Its QTc prolonging effect necessitates caution, precluding its use as a first-line treatment for first-episode schizophrenia.
• Sertindole presents a valuable alternative for patients with treatment-resistant schizophrenia or those who do not respond well to initial antipsychotic choices.